Elutia Inc. (ELUT) stock

ELUTNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/3022% below fair value

$0.82−0.06 (-6.69%)

Close on Nov 13, 2026Market cap $36.32MP/E –Yield –

Elutia gross margin

Gross margin is gross profit as a percentage of revenue.

Elutia's gross margin for the twelve months ending Sep 30, 2026 was 57.7%. For fiscal 2025 it was 53.7%, against 46.4% the year before. The highest annual figure on record is 53.7% in fiscal 2025.

Annual gross margin

Period	Period end	Value	Change (pts)
FY2025	Dec 31, 2025	53.7%	+7.2
FY2024	Dec 31, 2024	46.4%	+1.7
FY2023	Dec 31, 2023	44.7%	−4.1
FY2022	Dec 31, 2022	48.8%	+8.7
FY2021	Dec 31, 2021	40.1%	−8.0
FY2020	Dec 31, 2020	48.2%	+2.1
FY2019	Dec 31, 2019	46.1%	–

Quarterly gross margin

Change is against the same quarter a year earlier.

Period	Period end	Value	Change (pts)
Q3 FY2026	Sep 30, 2026	61.7%	+9.0
Q2 FY2026	Jun 30, 2026	59.6%	+6.7
Q1 FY2026	Mar 31, 2026	57.9%	+11.0
Q4 FY2025	Dec 31, 2025	56.7%	+9.8
Q3 FY2025	Sep 30, 2025	52.8%	+3.8
Q2 FY2025	Jun 30, 2025	52.9%	+8.4
Q1 FY2025	Mar 31, 2025	46.8%	+4.4
Q4 FY2024	Dec 31, 2024	46.9%	+10.8
Q3 FY2024	Sep 30, 2024	48.9%	+2.5
Q2 FY2024	Jun 30, 2024	44.5%	+1.8
Q1 FY2024	Mar 31, 2024	42.5%	−10.3
Q4 FY2023	Dec 31, 2023	36.2%	−2.6
Q3 FY2023	Sep 30, 2023	46.4%	+9.1
Q2 FY2023	Jun 30, 2023	42.7%	+11.5
Q1 FY2023	Mar 31, 2023	52.8%	+20.7
Q2 FY2022	Jun 30, 2022	38.8%	−7.4
Q1 FY2022	Mar 31, 2022	37.2%	−11.9
Q4 FY2021	Dec 31, 2021	31.2%	−17.1
Q3 FY2021	Sep 30, 2021	32.1%	−14.9
Q2 FY2021	Jun 30, 2021	46.2%	+2.1
Q1 FY2021	Mar 31, 2021	49.1%	−3.8
Q4 FY2020	Dec 31, 2020	48.3%	+7.7
Q3 FY2020	Sep 30, 2020	47.1%	−2.7
Q2 FY2020	Jun 30, 2020	44.1%	–
Q1 FY2020	Mar 31, 2020	52.9%	–
Q4 FY2019	Dec 31, 2019	40.6%	–
Q3 FY2019	Sep 30, 2019	49.8%	–